Q3 2025 ADC Therapeutics SA Earnings Call Transcript

Nov 10, 2025 / 01:30 PM GMT

Release Date Price: $4.21 (+4.21%)

Transcript 10-Q8-K

Key Points

Positve

ADC Therapeutics SA (ADCT) reported net product revenues of $15.8 million in Q3 2025, maintaining a stable quarterly run rate over the past two years.
The company secured a $60 million private placement, extending its cash runway to at least 2028.
Encouraging data from the phase 2 IIT of Zinlata in combination with rituximab in relapsed or refractory follicular lymphoma showed a 98.2% overall response rate.
ADC Therapeutics SA (ADCT) is advancing its clinical trials, with updates expected for Lotus 7 and Lotus 5 trials, potentially expanding the use of Zinlata.
The company is well-positioned to expand Zinlata into earlier lines of therapy for DLBCL and indolent lymphomas, with potential peak annual revenues of $600 million to $1 billion in the US.

Negative

Net product revenues decreased from $18 million in Q3 2024 to $15.8 million in Q3 2025.
The company reported a net loss of $41 million for Q3 2025, though slightly improved from a $44 million loss in Q3 2024.
Operating expenses were $45 million on a non-GAAP basis, indicating a need for continued cost management.
The competitive landscape for DLBCL treatments is evolving, with complex therapies like CAR T and bispecifics gaining traction.
The company faces challenges in expanding into the highly competitive follicular lymphoma market, where numerous agents are in phase 3 trials.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ADCT.N - ADC Therapeutics SA
Q3 2025 ADC Therapeutics SA Earnings Call
Nov 10, 2025 / 01:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning ladies and gentlemen, and welcome to the ADC Therapeutics Q3 2025 earnings conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press 0 for the operator. This call is being recorded on Monday, November 10, 2025. I will now turn the call over to Nicole Riley, head of head of investor relations and corporate communications for ADC Therapeutics. Nicole, please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.